Rezultati pretraživanja
  1. 4. velj

    $205M $2,040M. Is really worth 10x that of ? Seems like a stretch even with Adi factored in.

  2. 4. velj
    Odgovor korisniku/ci

    A rational Anti-CD47 combo trial should take an CD16a engager to steer hungry Macrophages to cancer cells that then may no longer hide via the 'do not eat me' signal

  3. 3. velj

    How’s that 1/31 mdacc start date going

  4. 3. velj

    condolences to Affimed team and CFO family

  5. 29. sij

    looks like AFM13-NK trial is ready to start

  6. prije 10 sati

    is $27 and is $2.7x ... what the hell ..

  7. prije 11 sati

    needs to break $2.77. Lot to ask for this rudderless floating turd.

  8. 4. velj

    Short sale volume (not short interest) for on 2020-02-03 is 55%. 21% 52% 60%

  9. 4. velj
    Odgovor korisnicima

    For targeting anti-CD47 in cancer could be an ideal partner connecting EGFR expression to macrophages / NK-cells

  10. 4. velj
    Odgovor korisniku/ci

    If only funds buy too, with positive news like this.... So far it seems and seem to go up most with positive NKcell news and progress.

  11. 3. velj
    Odgovor korisniku/ci

    The reported NK-trials are more like (licensed CAR switch) and (cord-blood derived NK-cells via MDACC) technology rather than or work

  12. 3. velj

    So far today up 6% , 2B market cap, new 52 week high up 6% 660M, market cap ....

    Prikaži ovu nit
  13. 3. velj

    burning investors money daily. Only average up, especially on weak stocks.

  14. 3. velj

    Sad day. Calm and measured, seems to have worked pretty much until his last days.

  15. 3. velj

    Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer

  16. 2. velj
    Odgovor korisniku/ci

    I really think makes breakthroughs by leaps and bounds leaving in dust, while Adi vigorously jerks off to every paycheck he gets which he didn't earn. At the same time Adi worshippers vigorously jerk off to images of Adi jerking off. Sometimes bending over too!

  17. 2. velj
    Odgovor korisnicima

    If I come back to in 2021 , I think it’ll still be $2.50 . Can you imagine where AFMD would trade if there was no Genentech deal ? It’d be $0.20 cents

  18. 31. sij
    Odgovor korisnicima

    According to Adi during a cc on 2019,the potentiel market for AFM 24 is between 3 and 20 billions $: two indications are known( lung and colorectal) and two other unknown yet.Let wait for the design in the end of March which may push the SP substantially higher IMO...

  19. 31. sij

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.